Clinical and virological data of the first cases of COVID-19 in Europe: a case series.
Adult
Aged, 80 and over
Betacoronavirus
/ isolation & purification
Blood
/ virology
COVID-19
China
Coronavirus Infections
/ diagnosis
Feces
/ virology
Female
France
/ epidemiology
Humans
Male
Middle Aged
Nasopharynx
/ virology
Pandemics
Pneumonia, Viral
/ diagnosis
RNA, Viral
/ isolation & purification
SARS-CoV-2
Travel
Urine
/ virology
Viral Load
Journal
The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
24
02
2020
revised:
11
03
2020
accepted:
12
03
2020
pubmed:
1
4
2020
medline:
4
6
2020
entrez:
1
4
2020
Statut:
ppublish
Résumé
On Dec 31, 2019, China reported a cluster of cases of pneumonia in people at Wuhan, Hubei Province. The responsible pathogen is a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the relevant features of the first cases in Europe of confirmed infection, named coronavirus disease 2019 (COVID-19), with the first patient diagnosed with the disease on Jan 24, 2020. In this case series, we followed five patients admitted to Bichat-Claude Bernard University Hospital (Paris, France) and Pellegrin University Hospital (Bordeaux, France) and diagnosed with COVID-19 by semi-quantitative RT-PCR on nasopharyngeal swabs. We assessed patterns of clinical disease and viral load from different samples (nasopharyngeal and blood, urine, and stool samples), which were obtained once daily for 3 days from hospital admission, and once every 2 or 3 days until patient discharge. All samples were refrigerated and shipped to laboratories in the National Reference Center for Respiratory Viruses (The Institut Pasteur, Paris, and Hospices Civils de Lyon, Lyon, France), where RNA extraction, real-time RT-PCR, and virus isolation and titration procedures were done. The patients were three men (aged 31 years, 48 years, and 80 years) and two women (aged 30 years and 46 years), all of Chinese origin, who had travelled to France from China around mid-January, 2020. Three different clinical evolutions are described: (1) two paucisymptomatic women diagnosed within a day of exhibiting symptoms, with high nasopharyngeal titres of SARS-CoV-2 within the first 24 h of the illness onset (5·2 and 7·4 log We illustrated three different clinical and biological types of evolution in five patients infected with SARS-CoV-2 with detailed and comprehensive viral sampling strategy. We believe that these findings will contribute to a better understanding of the natural history of the disease and will contribute to advances in the implementation of more efficient infection control strategies. REACTing (Research & Action Emerging Infectious Diseases).
Sections du résumé
BACKGROUND
On Dec 31, 2019, China reported a cluster of cases of pneumonia in people at Wuhan, Hubei Province. The responsible pathogen is a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the relevant features of the first cases in Europe of confirmed infection, named coronavirus disease 2019 (COVID-19), with the first patient diagnosed with the disease on Jan 24, 2020.
METHODS
In this case series, we followed five patients admitted to Bichat-Claude Bernard University Hospital (Paris, France) and Pellegrin University Hospital (Bordeaux, France) and diagnosed with COVID-19 by semi-quantitative RT-PCR on nasopharyngeal swabs. We assessed patterns of clinical disease and viral load from different samples (nasopharyngeal and blood, urine, and stool samples), which were obtained once daily for 3 days from hospital admission, and once every 2 or 3 days until patient discharge. All samples were refrigerated and shipped to laboratories in the National Reference Center for Respiratory Viruses (The Institut Pasteur, Paris, and Hospices Civils de Lyon, Lyon, France), where RNA extraction, real-time RT-PCR, and virus isolation and titration procedures were done.
FINDINGS
The patients were three men (aged 31 years, 48 years, and 80 years) and two women (aged 30 years and 46 years), all of Chinese origin, who had travelled to France from China around mid-January, 2020. Three different clinical evolutions are described: (1) two paucisymptomatic women diagnosed within a day of exhibiting symptoms, with high nasopharyngeal titres of SARS-CoV-2 within the first 24 h of the illness onset (5·2 and 7·4 log
INTERPRETATION
We illustrated three different clinical and biological types of evolution in five patients infected with SARS-CoV-2 with detailed and comprehensive viral sampling strategy. We believe that these findings will contribute to a better understanding of the natural history of the disease and will contribute to advances in the implementation of more efficient infection control strategies.
FUNDING
REACTing (Research & Action Emerging Infectious Diseases).
Identifiants
pubmed: 32224310
pii: S1473-3099(20)30200-0
doi: 10.1016/S1473-3099(20)30200-0
pmc: PMC7156120
pii:
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
697-706Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Type : CommentIn
Type : ErratumIn
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Lancet. 2013 Jun 29;381(9885):2265-72
pubmed: 23727167
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
PLoS One. 2014 Feb 14;9(2):e88716
pubmed: 24551142
Lancet Infect Dis. 2014 Jan;14(1):8-9
pubmed: 24355025
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
China CDC Wkly. 2020 Feb 21;2(8):113-122
pubmed: 34594836
Clin Chem. 2004 Jan;50(1):67-72
pubmed: 14709637
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Lancet. 2004 May 22;363(9422):1699-700
pubmed: 15158632
Nat Rev Microbiol. 2009 Jun;7(6):439-50
pubmed: 19430490
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
J Travel Med. 2020 Mar 13;27(2):
pubmed: 32052846
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
CMAJ. 2004 Jan 6;170(1):47-54
pubmed: 14707219
J Clin Microbiol. 2016 Apr;54(4):928-33
pubmed: 26763967